MedTrace Logo

Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer

NCT04068753 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-02-10

No results posted yet for this study

Summary

The purpose of this research study is to test the safety of Niraparib and dostarlimab as a combination treatment and see what effects (good and bad) this combination treatment has on patients with recurrent or progressive cervix cancer.

Conditions

  • Recurrent Cervix Cancer
  • Progressive Cervix Cancer

Interventions

DRUG

Niraparib

Niraparib: 200 mg, oral, once daily, days 1-21

DRUG

dostarlimab

dostarlimab: 500 mg IV, every three weeks for 4 cycles followed by 1000 mg every six weeks for up to two years

Sponsors & Collaborators

  • Tesaro, Inc.

    collaborator INDUSTRY

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Debra Richardson, MD · Stephenson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-26
Primary Completion
2026-12-31
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04068753 on ClinicalTrials.gov